Published in Mol Med Rep on October 30, 2014
A promising "TRAIL" of tanshinones for cancer therapy. Biomedicine (Taipei) (2015) 0.80
A dual PI3K/AKT/mTOR signaling inhibitor miR-99a suppresses endometrial carcinoma. Am J Transl Res (2016) 0.78
Regulation of miRNA-29c and its downstream pathways in preneoplastic progression of triple-negative breast cancer. Oncotarget (2017) 0.75
Alkannin inhibits growth and invasion of glioma cells C6 through IQGAP/mTOR signal pathway. Int J Clin Exp Med (2015) 0.75
Roles of Reactive Oxygen Species in Anticancer Therapy with Salvia miltiorrhiza Bunge. Oxid Med Cell Longev (2016) 0.75
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer (2010) 90.16
AKT/PKB signaling: navigating downstream. Cell (2007) 31.26
The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer (2002) 28.11
A checkpoint regulates the rate of progression through S phase in S. cerevisiae in response to DNA damage. Cell (1995) 6.00
The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther (2002) 4.73
Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J Clin Pharmacol (2005) 4.23
Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discov (2011) 4.05
Autophagy as a target for anticancer therapy. Nat Rev Clin Oncol (2011) 3.19
Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony. J Biol Chem (2010) 2.90
mTOR signaling in disease. Curr Opin Cell Biol (2011) 2.73
Breast cancer in Iran: an epidemiological review. Breast J (2007) 2.55
Regulatory roles of cyclin dependent kinase phosphorylation in cell cycle control. Curr Opin Cell Biol (1996) 2.53
Deregulation of the Akt pathway in human cancer. Curr Cancer Drug Targets (2008) 1.75
Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma. Cancer Res (2006) 1.70
Cip/Kip proteins: more than just CDKs inhibitors. Genes Dev (2004) 1.65
Lipid-regulated kinases: some common themes at last. Science (1998) 1.53
Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo. Oncogene (2007) 1.36
Integrin-dependent signal transduction regulating cyclin D1 expression and G1 phase cell cycle progression. Cancer Metastasis Rev (2005) 1.31
mTOR signaling pathway is a target for the treatment of colorectal cancer. Ann Surg Oncol (2009) 1.29
Tanshinone I effectively induces apoptosis in estrogen receptor-positive (MCF-7) and estrogen receptor-negative (MDA-MB-231) breast cancer cells. Int J Oncol (2008) 1.24
Growth inhibition and induction of apoptosis in MCF-7 breast cancer cells by Antrodia camphorata. Cancer Lett (2006) 1.20
New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists. Breast Cancer Res (2004) 1.20
Anticancer effects of tanshinone I in human non-small cell lung cancer. Mol Cancer Ther (2008) 1.20
Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy. Mol Cancer Ther (2002) 1.20
Targeting the PI3K/Akt/mTOR pathway for breast cancer therapy. J Mammary Gland Biol Neoplasia (2012) 1.14
Class IA phosphatidylinositol 3-kinase: from their biologic implication in human cancers to drug discovery. Expert Opin Ther Targets (2008) 1.13
PKB/Akt promotes DSB repair in cancer cells through upregulating Mre11 expression following ionizing radiation. Oncogene (2010) 1.12
Caspase 3 regulates phosphatidylserine externalization and phagocytosis of oxidatively stressed erythrocytes. FEBS Lett (2002) 1.12
Target of rapamycin signaling in leukemia and lymphoma. Clin Cancer Res (2010) 1.11
Antrodia camphorata inhibits proliferation of human breast cancer cells in vitro and in vivo. Food Chem Toxicol (2008) 1.06
Bioactive tanshinones in Salvia miltiorrhiza inhibit the growth of prostate cancer cells in vitro and in mice. Int J Cancer (2010) 1.05
Increased phosphorylation of Akt in triple-negative breast cancers. Cancer Sci (2007) 1.04
In vitro cytotoxicity of tanshinones isolated from Salvia miltiorrhiza Bunge against P388 lymphocytic leukemia cells. Phytomedicine (2003) 1.04
Tanshinone I suppresses growth and invasion of human breast cancer cells, MDA-MB-231, through regulation of adhesion molecules. Carcinogenesis (2008) 1.03
Mammalian target of rapamycin regulates the growth of mammary epithelial cells through the inhibitor of deoxyribonucleic acid binding Id1 and their functional differentiation through Id2. Mol Endocrinol (2006) 0.97
Tanshinone IIA inhibits human breast cancer cells through increased Bax to Bcl-xL ratios. Int J Mol Med (2008) 0.97
Obesity associated alterations in the biology of adipose stem cells mediate enhanced tumorigenesis by estrogen dependent pathways. Breast Cancer Res (2013) 0.96
NK cells inhibit T cell proliferation via p21-mediated cell cycle arrest. J Immunol (2005) 0.96
MicroRNA-34a modulates chemosensitivity of breast cancer cells to adriamycin by targeting Notch1. Arch Med Res (2012) 0.96
Anti-proliferative activity of Bupleurum scrozonerifolium in A549 human lung cancer cells in vitro and in vivo. Cancer Lett (2004) 0.93
The PI3K/Akt pathway as a target in the treatment of hematologic malignancies. Anticancer Agents Med Chem (2009) 0.92
Inactivation of PI3k/Akt signaling pathway and activation of caspase-3 are involved in tanshinone I-induced apoptosis in myeloid leukemia cells in vitro. Ann Hematol (2010) 0.92
Cytotoxicity of major tanshinones isolated from Danshen (Salvia miltiorrhiza) on HepG2 cells in relation to glutathione perturbation. Food Chem Toxicol (2007) 0.91
Tanshinones inhibit the growth of breast cancer cells through epigenetic modification of Aurora A expression and function. PLoS One (2012) 0.90
Tanshinone IIA inhibits leukemia THP-1 cell growth by induction of apoptosis. Oncol Rep (2009) 0.90
PI3K/AKT/mTOR signaling pathway inhibitors in proliferation of retinal pigment epithelial cells. Int J Ophthalmol (2012) 0.89
Bioactive tanshinone I inhibits the growth of lung cancer in part via downregulation of Aurora A function. Mol Carcinog (2012) 0.82